✦ LIBER ✦

PDB33 COST-CONSEQUENCE ANALYSIS OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES INA FRENCH SETTING

✍ Scribed by AJ Palmer; WJ Valentine; S Roze; R Chen; S Gabriel; B Bregman; N Mehin; HH Parving

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-consequence analysis in a French se

✍ AJ Palmer; R Chen; WJ Valentine; S Roze; B Bregman; N Mehin; S Gabriel 📂 Article 📅 2006 🏛 Masson Editeur 🌐 French ⚖ 122 KB

PDB40 COST-UTILITY ANALYSIS IN A USA SET

✍ AJ Palmer; R Chen; WJ Valentine; S Roze; S Gabriel; N Mehin; B Bregman; R Rodby 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

PDB16 SELF MONITORING OF BLOOD GLUCOSE I

✍ AJ Palmer; ME Minshall; WJ Valentine; V Foos; SL Tunis 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

196: Cost-Effectiveness of Aliskiren as

✍ James L. Palmer; Veronica C. Munk; Robert W. Kotchie; Gabor Vincze; Alan Charney 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 184 KB

CV4 IRBESARTAN IS PROJECTED TO BE COST A

✍ AJ Palmer; L Annemans; S Roze; M Lamotte; P Lapuerta; S Gabriel; R Chen; P Carit 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

An Asian Regional Analysis of Cost-Effec

✍ Lieven Annemans; Nadia Demarteau; Shanlian Hu; Tae-Jin Lee; Zaher Morad; Thanom 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 396 KB